Lawmakers Debate Picks For FDA Chief; Possibilities Include Drug Safety Director Woodcock
Main Category: Regulatory Affairs / Drug ApprovalsAlso Included In: Sexual Health / STDs; Women's Health / Gynecology
Article Date: 08 Dec 2008 - 0:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Debate over whether any current FDA officials should be named as successor to current FDA Commissioner Andrew von Eschenbach and how quickly the decision should be announced is dividing congressional officials, "reflecting a divergence of views ... on how to fix the FDA's problems," the Wall Street Journal reports. According to Congressional aides, Democratic officials have discussed naming Janet Woodcock, director of FDA's drug safety division, as commissioner, and individuals close to the pharmaceutical industry also have mentioned her as a possible pick after von Eschenbach's predicted departure.
The Journal reports that Woodcock has been "involved in several controversies" during her tenure with FDA, including over FDA's delayed approval of nonprescription sales of the emergency contraceptive Plan B amid political pressure. The agency as a whole has "come under fire from both parties in Congress in recent years for problems related to pharmaceutical safety," in which Woodcock, as drug safety director, has been involved, according to the Journal. Other controversies involving Woodcock include the 2004 withdrawal of the painkiller Vioxx and the recent contamination of the blood thinner heparin from Chinese ingredients.
Rep. Bart Stupak (D-Mich.) in a letter to President-elect Barack Obama on Wednesday called for a "complete change in the FDA's leadership" and "encourage[ed]" him to not appoint any senior FDA employees as commissioner. He said current senior officials are "too close with the industries they regulate, creating a question of who they are working for." The Journal reports that other possible appointees to the position include Joshua Sharfstein, head of the Baltimore Health Department, and Steven Nissen, chief of cardiovascular medicine at the Cleveland Clinic (Mundy, Wall Street Journal, 12/5).
Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.
© 2008 The Advisory Board Company. All rights reserved.
Visit our regulatory affairs / drug approvals section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/132065.php>
APA
http://www.medicalnewstoday.com/releases/132065.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



